Division of Cardiology, Saint Louis University School of Medicine, Saint Louis, MO 63110, USA.
Med Clin North Am. 2012 Sep;96(5):943-54. doi: 10.1016/j.mcna.2012.07.004.
Inotropic therapy remains an option in the management of patients with advanced heart failure symptoms from systolic dysfunction who do not respond to conventional therapies. The decision to use this class is largely predicated on an accurate evaluation of the patient's fluid and perfusion status. Selection of the appropriate agent and dosing regimens requires an understanding of the underlying pathophysiology of heart failure and concomitant therapy. Most important, the goals of care should be stated clearly, given inherent risks associated with this class of drug.
在对常规治疗无反应的、有收缩功能障碍的晚期心力衰竭症状的患者的管理中，仍可选择正性肌力治疗。使用该类药物的决定主要取决于对患者液体和灌注状态的准确评估。选择合适的药物和剂量方案需要了解心力衰竭的潜在病理生理学和伴随治疗。最重要的是，鉴于此类药物的固有风险，应明确说明治疗目标。
